|Articles|October 1, 2014
Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Advertisement
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Advisory Committee Backs RP1 for Advanced Melanoma
2
Living With Lung Cancer, Not Dying From It: One Survivor's Story of Hope
3
Same-Day Discharge and Single-Incision Surgery Are Changing Rectal Cancer Care
4
Oncology Researcher Brings Science, Compassion and Personal Loss to Cancer Care
5